Biovac clinches deal to make oral cholera vaccine
Licensing and technology-transfer agreement with the International Vaccine Initiative offers a timely boost to Africa’s health security
23 November 2022 - 17:47
State-backed vaccine manufacturer Biovac has signed a licensing and technology-transfer agreement with the International Vaccine Initiative (IVI), to manufacture an oral cholera vaccination, a move expected to boost its in-house capacity and bolster Africa’s health security.
The deal with the South Korean non-profit organisation comes as a surge in cholera outbreaks around the world has heightened awareness of a long-standing global constraint on the supply of vaccines...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.